Biotechnology News

Announced Proposed Merger with Avere TherapeuticsPreserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities BELTSVILLE, Md., Aug. 06, 2026 (GLOBE...

$37 Million of TPOXX Sales Generated in the Second QuarterCorporate Update Conference Call Today at 4:30 PM ET NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq:...

BOCA RATON, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced its...

- Estudio exploratorio VIRAGE2, diseñado para ajustar la pauta posológica de VCN-01 con el fin de su posible evaluación en un futuro ensayo clínico pivotal de Fase III sobre el adenocarcinoma ductal...

August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with...

SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also...

Easy Environmental Solutions Is Saving 1000’s Of Trees From Disease & Forced Removal

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the...

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial...

Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026Concluded last patient last visit in...